Margin operasi CEL-SCI Corp. (CVM)

CEL-SCI Corporation - logo grafis emiten CVM

CEL-SCI Corporation lacks pricing power due to the absence of commercial sales. The company's operations rely on the development of immunotherapy to combat head and neck tumors. The quarterly operating margin on GURU.Markets visualizes profitability, where the value of 0.00 characterizes this level. Prospects depend on Multikine test results, FDA approval, and patient survival data.

CVM - Tingkat bathi operasi CEL-SCI Corp. ing rentang 04.07.2022 - 19.11.2026

Rincian metrik lan analitis perusahaan CEL-SCI Corp (CVM)

- rega saham lan konsensus proyeksi valuasi:
Pambiji fundamental perusahaan:CVM, cel-sci.com
Barang utama CEL-SCI Corp.

Operating margin determines cost management efficiency by comparing operating profit before interest and taxes to total revenue. By analyzing operating profitability, an investor can see how bioreactor robotization and the minimization of human error in CEL-SCI Corporation immunotherapy production optimize internal costs, directly impacting the final fundamental value of the business.

Karo sapa CEL-SCI Corporation saingan

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi ostherapies.com OSTX|RADX: Rentabilitas dodolan miturut bathi operasi|ARTV: Margin dodolan operasi|ANL (Adlai Nortye) - Rentabilitas dodolan miturut bathi operasi|Veru (VERU) - Rentabilitas operasi|Margin dodolan operasi Tempest Therapeutics Inc|Rentabilitas operasi Xilio Therapeutics|Rentabilitas dodolan miturut bathi operasi RENB (Renovaro Inc.)|Rentabilitas operasi Mural Oncology PLC (MURA)|Margin operasi Kairos Pharma (KAPA)|Rentabilitas operasi onkuretherapeutics.com OKUR|GDTC: Rentabilitas dodolan miturut bathi operasi|CRIS: Margin dodolan operasi|apollomicsinc.com (APLM) - Margin dodolan operasi|THAR: Margin operasi|Margin dodolan operasi Advanced Biomed Inc.|Margin dodolan operasi GNPX|Rentabilitas dodolan miturut bathi operasi CLDI (Calidi Biotherapeutics)|Margin operasi SBFM|Xenetic Biosciences, Inc. - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Salarius Pharmaceuticals SLRX|Margin operasi purple-biotech.com PPBT|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi